New strategies in hepatocellular carcinoma: Genomic prognostic markers

Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Helena Cornella, Josep M. Llovet

Research output: Contribution to journalReview article

87 Citations (Scopus)

Abstract

Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis.

Original languageEnglish (US)
Pages (from-to)4688-4694
Number of pages7
JournalClinical Cancer Research
Volume16
Issue number19
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
MicroRNAs
Epigenomics
Neoplasms
Survival
Liver Neoplasms
Life Expectancy
Genes
Liver Diseases
Fibrosis
Biomarkers
Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Villanueva, A., Hoshida, Y., Toffanin, S., Lachenmayer, A., Alsinet, C., Savic, R., ... Llovet, J. M. (2010). New strategies in hepatocellular carcinoma: Genomic prognostic markers. Clinical Cancer Research, 16(19), 4688-4694. https://doi.org/10.1158/1078-0432.CCR-09-1811

New strategies in hepatocellular carcinoma : Genomic prognostic markers. / Villanueva, Augusto; Hoshida, Yujin; Toffanin, Sara; Lachenmayer, Anja; Alsinet, Clara; Savic, Radoslav; Cornella, Helena; Llovet, Josep M.

In: Clinical Cancer Research, Vol. 16, No. 19, 01.10.2010, p. 4688-4694.

Research output: Contribution to journalReview article

Villanueva, A, Hoshida, Y, Toffanin, S, Lachenmayer, A, Alsinet, C, Savic, R, Cornella, H & Llovet, JM 2010, 'New strategies in hepatocellular carcinoma: Genomic prognostic markers', Clinical Cancer Research, vol. 16, no. 19, pp. 4688-4694. https://doi.org/10.1158/1078-0432.CCR-09-1811
Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R et al. New strategies in hepatocellular carcinoma: Genomic prognostic markers. Clinical Cancer Research. 2010 Oct 1;16(19):4688-4694. https://doi.org/10.1158/1078-0432.CCR-09-1811
Villanueva, Augusto ; Hoshida, Yujin ; Toffanin, Sara ; Lachenmayer, Anja ; Alsinet, Clara ; Savic, Radoslav ; Cornella, Helena ; Llovet, Josep M. / New strategies in hepatocellular carcinoma : Genomic prognostic markers. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 19. pp. 4688-4694.
@article{167c0dd70c754e0da6d772c71be35438,
title = "New strategies in hepatocellular carcinoma: Genomic prognostic markers",
abstract = "Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis.",
author = "Augusto Villanueva and Yujin Hoshida and Sara Toffanin and Anja Lachenmayer and Clara Alsinet and Radoslav Savic and Helena Cornella and Llovet, {Josep M.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-09-1811",
language = "English (US)",
volume = "16",
pages = "4688--4694",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - New strategies in hepatocellular carcinoma

T2 - Genomic prognostic markers

AU - Villanueva, Augusto

AU - Hoshida, Yujin

AU - Toffanin, Sara

AU - Lachenmayer, Anja

AU - Alsinet, Clara

AU - Savic, Radoslav

AU - Cornella, Helena

AU - Llovet, Josep M.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis.

AB - Accurate prognosis prediction in oncology is critical. In patients with hepatocellular carcinoma (HCC), unlike most solid tumors, the coexistence of two life-threatening conditions, cancer and cirrhosis, makes prognostic assessments difficult. Despite the usefulness of clinical staging systems for HCC in routine clinical decision making (e.g., Barcelona-Clinic Liver Cancer algorithm), there is still a need to refine and complement outcome predictions. Recent data suggest the ability of gene signatures from the tumor (e.g., EpCAM signature) and adjacent tissue (e.g., poor-survival signature) to predict outcome in HCC (either recurrence or overall survival), although independent external validation is still required. In addition, novel information is being produced by alternative genomic sources such as microRNA (miRNA; e.g., miR-26a) or epigenomics, areas in which promising preliminary data are thoroughly explored. Prognostic models need to contemplate the impact of liver dysfunction and risk of subsequent de novo tumors in a patient's life expectancy. The challenge for the future is to precisely depict genomic predictors (e.g., gene signatures, miRNA, or epigenetic biomarkers) at each stage of the disease and their specific influence to determine patient prognosis.

UR - http://www.scopus.com/inward/record.url?scp=77957552077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957552077&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1811

DO - 10.1158/1078-0432.CCR-09-1811

M3 - Review article

C2 - 20713493

AN - SCOPUS:77957552077

VL - 16

SP - 4688

EP - 4694

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -